| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 506501 | 1 mg | $175 | ||
| 506502 | 5 mg | $480 | ||
| 506503 | 20 mg | $960 |
| Clone | Tusamitamab |
|---|---|
| Application | Flow cytometry, animal model study |
| Host Species | Mammalian cells |
| Format | Liquid |
| Product Description | Tusamitamab Biosimilar, Human CEACAM5 Monoclonal Antibody |
| Isotype | Human IgG1 |
| Regulatory Status | RUO |
| Clonality | Recombinant |
| Immunogen | Human CEACAM5 |
| Species specificity | Human |
| Purity | >95% by reducing SDS-PAGE |
| Grade | In vivo |
| Min Sample Size | 1 mg |
| Storage Conditions | 4ºC |
| Maximal Shelf Life | 12 months |
| Synonyms | CD66e |
| See All Formats | Clone Tusamitamab |
Tusamitamab, as a therapeutic, is an antibody–drug conjugate (ADC) that combines a humanized monoclonal antibody targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) with a potent cytotoxic payload. Structurally, the antibody component belongs to the human immunoglobulin G1 kappa (IgG1κ) subclass and has a molecular mass of approximately 150 kilodaltons (kDa). It is composed of two identical heavy chains and two identical light chains linked by disulfide bonds in the Y-shaped conformation typical of IgG molecules. The antibody is produced recombinantly in mammalian cell systems, such as Chinese Hamster Ovary (CHO) cells, ensuring proper folding and glycosylation.
The variable regions of the heavy (VH) and light (VL) chains contain complementarity-determining regions (CDRs) that mediate high-affinity binding to a specific extracellular epitope on CEACAM5, a cell-surface glycoprotein involved in cell adhesion and intercellular signaling. This antigen is largely restricted to certain epithelial lineages, making it an accessible and stable target for molecular binding studies. The antibody’s specific recognition enables selective internalization when bound to CEACAM5 at the cell membrane.
The Fc (fragment crystallizable) region of Tusamitamab provides structural stability and extended half-life via neonatal Fc receptor (FcRn) recycling.
Anti-Human CEACAM5 (Tusamitamab Biosimilar) TDS
Have a product or application question? Consult our FAQs or contact us.
